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Ajulemic Acid Induces Cell Death in Retinobla toma Cell

emil) A. Evans
A bstract

Retinoblastoma is a cancer of the retina affecting one in e\ ery 15.000-20.000
births. It is normally diagnosed in infancy or early childhood and although it is treatable.
enucleation is commonly required. Other treatments include radiation, photocoagulation,
or cryotherapy and are often followed by chemotherap). ln an attempt to find an
alternate method of treatment that lowers the frequency of enucleation and the
serious side-effects resulting from current treatments, ajulemic acid (AJA). aS) nthetic
derivative of Cannabis. has been used to treat retinoblastoma cells. Thus far. significant
cell death has occurred among retinoblastoma cells that have been treated with AJA
concentrations of as low as 50 ~-tM. We are also currently investigating how the AJA
treatment of retinoblastoma cells compares with carboplatin treatment, one of the leading
chemotherapy drugs currently used in treating retinoblastoma.

ln trod uction

Retinoblaslomu
The purpose of our research was to investigate ajulemic acid's (AJA) ability to
induce retinoblastoma cell death and to compare it V\ ith one current chemotherapy
method of treatment, the drug carboplatin (CBP).
Retinoblastoma (Rb) is a pediatric cancer that develops in the retina of the eye
and is the most frequent primary eye grow1h found in infants and children (Blachford.
2002). This disease occurs in nearly one out of every 15.000-20.000 live births world-

\\ide (Aerts, 2006). Rb usually occurs and is diagnosed before the age of 4 (Beers, 2003)
I lov.ever, it can be identified in patients at the ages of 5-7 years (Murphree and Clark) an
even more rarely in adulthood (Aerts. 2006). A consistenc) of cases among all races has
been observed and there is no significant difference in the number of cases betvveen male
or female or between incidences in the lefl or right eye (Kufe et al., 2003). In developed
countries. there is a high survival rate for children with retinoblastoma: however children
~ ith

the disease in underdeveloped parts of the world rarely survive (Murphree and

Clark).
There are a variety of ways that retinoblastoma can present, but the most common
signs are leukocoria, a white pupillaf) reflex, seen in 50% of patients and strabismus,
crossed eyes, observed in 25% of patients (Blachford, 2002). Other symptoms may
include red painful eye, poor vision, iris rubeosis (abnormal blood vessel gro~th of the
iris), orbital cellulites (orbital tissue infection), hypopyon (pus in the eye), amblyopia
("lazy eye"), congenital glaucoma, exophthalmia (eyeball protrusion) and heterochromia
(difTerence in iris coloration) (Aertes, 2006: Blachford, 2002).
Retinoblastoma develops in a few different \Vays. Endophytic growth, most
common!) observed, refers to v.hen retinoblastoma grows into the vitreous cavity
outward from the retina toward the eye's center. Gro'vth of the tumor into the choroid
and away from the underside of the retina is referred to as exophytic

gro~th.

Exophytic

growth is frequently associated with retinal detachment and the spread of the tumor into
the choroid and optic nerve. A more uncommon growth pattern is known as diffuse
infiltrating in which a mass is not formed, rather the tumor is dispersed throughout the
retina (Murphree and Clark).
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Retinoblastoma Etiology

Retinoblastoma can be inherited or can occur sporadically. About 45% of cases
are the nonhereditary form, or non-germinal, and approximately 55% of the cases are
inherited. or germinaL in which there is an immediate family member 'vvho has previously
been diagnosed with the disease (Aertes, 2006). The nonhereditary form nom1ally occurs
unilaterally and is unifocal. a single tumor that affects one eye (Blachford. 2002). The
hereditary form always presents either bilaterall) (affecting both eyes) or unilaterally and
multifocal (multiple tumors in one eye).
When the disease is inherited. a germline mutation has typically already occurred
in one of the alleles of the retinoblastoma gene (RB-1) that codes for the protein pRB. If
a person inherits one mutated allele and one normaJ allele. the person will not develop
cancer as long as the normal allele does not become mutated. However. \\hen a somatic
mutation of the second allele occurs. the gene v.. ill code or miscode for the defective pRB
and cell division will no longer be regulated. This lack of regulation results in cancer.
Instead of inheriting mutations. people with sporadic retinoblastoma have tv.·o
independent somatic mutations occurring in both alleles of the RB-1 gene. Again. the
correct coding of pRB is prevented and cancer resulrs. This idea that retinoblastoma is
the result of two mutational events is known as Knudson's two hit hypothesis (Tobias and
Black. 2002).
Due to pRB 's involvement in other types of cancers as well as retinoblastoma, the
patients that have a genninal mutation are at higher risks for developing nonocular
neoplasms (Narins, 2000). Other cancers that are linked to a mutated RB-I gene include
cancer of the breast. brain, or prostate. osteosarcoma. soft tissue sarcoma. leukemia and
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other sporadic cancers. Another risk. for those '"'ith a germline mutation is .. trilateral
retinoblastoma"' '"hich imohes a pediatric tumor in the midbrain (MacPherson, 2008).
fhe cause of retinoblastoma has been linked to lo5s of function of the tumor
suppressor retinoblastoma gene (RB-I) at chromosome location I 3q 14 (Tobias and
Black). I"here are 27 exons that encode the RB-I gene ranging from 3 I to l ,889 base
pairs (Claudio, et al., 2002). RB-1 codes for the protein pRB, a nuclear phosphoprotein
that is part of a pathway for cell division regulation. differentiation, apoptosis. and other
important processes (MacPherson. 2008). If pRB does not function correctly due to its
absence or gene mutation. uncontrolled cell proliferation is occurs leading to the
development of cancer (Brigham, 2000). J Jo,,e, er. recent studies have suggested an
additional mutation is needed for retinoblastoma to present.
There are three proteins that make up'' hat are kno'<m as the "pocket proteins:·
fhcy include pRB. p107. and p103. Named for their pocket domain. they are important
for binding E2f transcription factors and the) form part of a signal-transduction path"' a)
k.nov.n as the RB pathway. These pocket proteins are similar in that all three consist of
an amino-tcrn1inal domain. two conserved domains that male up the pocket region. a
spacer region. and a carboxy-terminal domain. 1 he) differ in function and the specific
E2f transcription factors that they bind to. Interestingly. high p130 levels have been
found in rctinomas (benign retinal tumors) and not in ncarb) retinoblastoma. This
finding suggests the progression of retinoma to retinoblastoma rna) be linked to the lack
of pI 30. fhe p 130 might also be a tumor suppressor gene. Due to the discover) of
consistent abnormalities in other chromosomes. the deletion of RB-I rna) not be enough
for retinoblastoma to occur (MacPherson. 2008).
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Retinoblastoma Diagnosis & Treatment
Retinoblastoma is generally diagnosed using the results of a fundoscopy exam
and sometimes with the aid of ultrasound, magnetic resonance imaging (MRI) and/or
computed tomography (CT). Ocular fundoscopy is the process in which, under general
anesthesia. the retina is observed using an indirect ophthalmoscopy. The lesion can be
seen as a white twnor surrounded with irregularly arranged blood vessels. An ocular
ultrasound expresses a mass made up of fine calcifications. When there is local extension
of Rb. MRI is usually used to illustrate extensions of the twnor into the optic nerve,
anterior chamber, and fat of the orbital. Intraocular tumors that are higher in density than
the vitreous body are typically observed in using CT (Aertcs, 2006).
Treatment is dependent upon the follo"'ring types of retinoblastoma and stages of
the disease; bilateral, unilateral, multifocaJ, unifocal. number oftwnors, size of tumors.
and disease extension. Two classification systems that are used to group retinoblastoma
are the Reese Ellsworth classification and the ABC classification. After Rb staging has
been determined. treatment is decided and may include a number of the following:
enucleation, external beam radiation therapy. cryotherapy, tTanspupillary thern1olherapy.
laser photocoagulation. brachytherapy, chemotherapy (Aertes, 2006).
Enucleation (the complete removal of the eyeball) is recommended in certain
situations that include large tumors, retinal detachment. and loss of functional vision.
Although it can be traumatic, it is usually successful. Also successful is external beam
radiation therapy: however, there are many adverse side effects that include secondary
non-ocular malignancies, cataracts, radiation retinopathy (bleeding and exudates of the
retina), impaired vision, temporal bone suppression and deformities (De Pouer, 2002;
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Abramson and Servodidio, 1997). In an attempt to a\oid enucleation and external beam
radiation therapy, first-line chemotherapy is often used followed by local treatment (De
Potter. 2002).
Chemotherapy options include chemotherapy injections into the bloodstream
(intravenous), subconjunctival chemotherapy (applied locally underneath the conjunctiva)
and systemic chemotherapy (taken orally or injected into the muscles). Chemotherapy
drugs commonly used for treating Rb include carboplatin, vincristine, and/or etoposide.
After these tumors ha\C been chemoreduced they can be treated ~ith the more local
treatments (De Potter, 2002).
Laser photocoagulation is the procedure of shining a beam of light through the
pupil to pennanently destroy the vessels feeding the tumor. Transpupillary
thennotherapy uses an infrared laser to induce hyperthermia on the tumor. Adverse side
effects can include optic disc and focal iris atrophy. Cryotherapy is a procedure that
denatures smaller retinoblastoma tumors by freezing them. Brach)- therapy is the suture
of an iodine-125 ( 125 f) plaque to the tumor and subsequent removal to reduce tumor size.
This procedure aims to reduce excess radiation and is often used in place of external
beam radiation (De Potter, 2002; Abramson and Servodidio. 1997; Kufe. et al., 2003).

Cannabinoids
Several studies have examined the medicinal properties of Cannabis's main active
component THC (tetrahydrocannabinol). However. due to its psychoactive properties
and the build-up of resistance. other cannabinoids have been investigated to find a more
effective phannaceutical. A group of cannabinoids that are T J JC metabolites actually
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lack psychoactive effects and are caJ ied cannabinoid acids. These acids include all of the
cannabinoids' carboxylic acid metabolites and their man-made analogs. The primary
metabolite of the cannabinoid acids, derived after the oxidative metabolism ofTHC. is
THC-11-oic acid. I lowever, to make it more potent for pharmaceutical uses. the
synthetic analog of THC-11-oic acid called ajulemic acid (dimethylheptyl-TIIC-11-oic
acid) or AJA was developed (Structure sho'W'll in Figure I) (Zurier). AJA has been found
to relieve pain, reduce inflammation. and have anti-tumor effects without producing
psychoactivity (Recht, 200 I).
Ajulemic acid (C25H3604) has a molecular weight of 400.55 g/mol and is stable as
a white crystalline solid. It is easily dissolved in many organic solvents and aqueous
buffers 'With a pii above 8 (Burstein. 2005).

COOH

Figure 1. tructure of Ajulcmic Acid

There has been much research conducted in an attempt to determine AJA 's mode
of action. Although there are still many unknowns, several propositions have been made.
First!), it has been identified that AJA is highly stereospecific points to the idea that its
mechanism is receptor mediated (Burstein, 2004). There is evidence that AJA
moderately binds to CB1 and CB2 receptors; however, this is contradictory with AJA"s
non-psychoactivity (Burstein, 2005). CB 1 receptors are found throughout the peripheral
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nervous system and the central nervous system. The areas in which the receptors are
most heavil:> expressed (the hippocampus. cortex, basal ganglia_ cerebellum, and spinal
cord) account for the memory. cognitive, and movement effects of cannabinoids. The
actual binding to the CB receptors activate G-proteins that affect many signal pathways

b; activation or inhibition (CN forum).
When the cannabinoid receptors are activated by TI IC. the activated 0-proteins
inhibit calcium channels dependent upon voltage gradients. sodium channels. and
adenylate cyclase. In addition. the G-proteins stimulate potassium channels and the
MAPK signaling pathway. In all, the cell's cAMP concentration is decreased leading to
neurotransmission inhibition. The sum of these affected pathways result in the euphoria
effects involved in using Cannabis (CNSforum). Therefore. it has been suggested AJA
may activate these receptors while antagonizing the pathway needed for the psychotropic
effects (Brecht. 2005). In addition, there still may be other receptors with which AJA
interacts, such as strychnine-sensitive a 1- and a 1P-glycine receptors (Ahrens. et al., 2008)
or the isotope 'Y of the peroxisome proliferator-activated receptor (PPAR-y) (Ambrosio. et
at.. 2007). Further research should be conducted to detem1ine the receptors to which
AJA binds both directly and indirectly.

Carhop/at in
Carboplatin (CBP) is a chemotherapy drug that is currently being used in the
treatment of several cancers including retinoblastoma. CBP (molecular weight 3 71.25
g/mol) is made up of a platinum-coordinated complex and is toxic to cells by alkylating
DNA (Eljarrat-Binstock. et aL 2008).
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0

0
Figu re 2. Structure of Carboplatin
Not onJy can carboplatin be used with other chemotherapy drugs intravenously, it
has also been used singularly as a periocular injection (Figure 2) (Schmack, eta!., 2006).
However, a major side effect encountered with carboplatin periocular injections is
ischemic optic neuropathy (Schmack, et aJ .. 2006). Another accepted use is the
subconjunctival injection of carboplatin. Side effects for this procedure include
endophthalmus. atrophy of the optic nerve, and myelin sheath and nerve fiber loss
(Kiratli. 2006).

lnltll«ular
rc{inobl:lStoma

Figure 3. Periocular carboplatin inj ection.
From: Schmack: The American Journal of Ophthalmology, Volume 142(2).August
2006.311. © 2006 Elsevier Inc.
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Materials

Ajulemic acid (AJA)

Ajulemic acid (AJA). dimethylheptyi-Tl IC- 11-oic acid was prepared in dimethyl
sulfoxide (OMSO) to a final stock concentration of 10 mM.

Carboplatin (CBP)

Carboplatin (CBP) stock was obtained from Sigma-Aldrich and was prepared in
sterile phosphate buffer saline (PB ) or ethanol (EtOI I) to a stock concentration of 10
mM.

Cell Culture

Y-79 (human retinoblastoma) suspension cell line was obtained from ATCC and
grov.n in RPMI-1640 medium containing a final concentration of 10% fetal bovine serum
and was cultured at 37 C v.ith 5.0% C0 2. Primary mice microglia and astrocytes were
obtained from UAMS.

Methods

MTSAssay

Y-79 cell viability was determined by measuring mitochondrial activity using an
MT assay composed of [3-(4.5-dimethylthiazone-2yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophen) I)-2II-tetrazolium] and an electron coupling reagent (phenazine
methosulfate) (Promega). MT solution was prepared by adding 42 mg ofMT Reagent
Powder to 21 mL of DPBS. mixed on stir plate for 15m in, and filter-sterilized through a

10

0.2 !lin filter. MTS (40 IlL) were added to each well of a 96-well plate. and the plate was
incubated at 37"C for 1 bour. The plate was then read in a plate reader (TECAN infinite
series) and absorbance was measured at wavelength of 490 nm.

MTT Assay
An MTT (3-(4.5-dimethylthiazone-2yl)-2,5-diphenyltetrazolium bromide) assay
was used to assess cell viability of primary microglia and astrocytes. MTT solution was
prepared by diluting MTT 1:50 with culture medium. Cell culture media was removed
from cells and replaced with 500 IlL MTT solution and incubated at 3 TC for one hour.
MIT solution was removed and cells were lysed by adding 500 IlL DMSO/well. Plates
were rocked for 30 min and read on a plate reader (TECAN infinite series) at570 nm.

ELISA Assay
Caspase-3 levels were measured using an enLyme-linked immunosorbent assay
according to manufacturer's recommendations (BD Bioscience).

Neuroprolection
Mouse cortical neurons were obtained from Lonza. They were plated in 36 wells
of a 96-well plate and cultured according to manufacturer's recommendations. Fourteen
days after plating. cells were treated with either AJA, JNF-r (interferon gamma). both or
neither as indicated for 72 hr. MTS assays were then run as previously described to
assess cell viability.
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Results
Cell Density

In order to determine the ideal cell density at which Y-79 Rb cells grew the best
and reacted most towards the treatment, multiple cell densities were investigated. The
cells were plated in 5 various densities ranging from 4x 104 cells/well to 4x I 05 cells/well
in 6 wells each of the 96-well plate. After 24 hr. wells 1-3 of each density were left
untreated and wells 3-6 of each density were treated with 50 J..lM ajulemic acid. An MTS
assay was used to measure the cell viability by assessing the mitochondrial activity. The
MTS reagent is a chemical that reacts with an enzyme present when the mitochondria are
active. This reaction yields a so luble purple precipitate that can be measured in intensity
on a plate reader at 490 run. Cell viability was compared at each density with the
untreated wells. Greatest cell viability loss due to AJA treatment was observed at the cell
den sity 3.1 x 105 cells/well (Figure 4 ).
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Figure 4. Cell Density.
Y-79 Rb cells were plated with indicated densities and treated in triplicate with 50 ).I.M
AJA . Cell viability was measured using MTS assay 72 hr later. Values represent the
average cell viabi lity for triplicate cultures. Standard errors are indicated. Asterisks
designate statistical significance of p<0.05. Greatest difference in viability between
untreated and treated wells was observed at the cell density 3.1 xI 05 cells/well.
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The Effects ofDMSO on the viability of Y-79 Rb cells
In order to assess the effects of the solvent OM 0, in which AJA is dissolved. Y79 cells were plated in a 96-welJ plate at a density 3.lxl05 ceJVwell. Wells were treated
in triplicate 24 hr later with the following increasing ajulemic acid concentration
equivalents of dimethyl sulfoxide (DMSO): 50 eq, 75 eq, 100 eq. Cell viability was
measured using an MTS assay. Our results indicate that DMSO does not significantly
affect the viability ofY-79 RB cells (Figure 5) .

.c

m

>
Q,)

u

Figure 5. Y -79 Cultures with Dimethyl sulfoxide (DMSO) treatment.
Cells were treated 24 hr after plating with DM 0 in equivalent volumes or AJA
treatments as indicated

to

account for any cell death that was not caused by AJA. Cell

viability was measured using MTS assay 72 hr later. Values represent the average cell
viability for triplicate cultures. Standard errors are indicated.
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Ajulemic Acid's Effect on Y- 79 Rb cell viability

Y-79 cells were plated in a 96-well plate at a density 3. 1xI 05 cells/well. Wells
were treated in triplicate 24 hr later with the following increasing ajulernic acid (AJA)
concentrations: 25

~M,

50 ~M, 75

~M.

I00 ~M. After 72 br, cell viability was measured

using a MTS assay. Our data indicates significant cell death in Y-79 RB ce!Js when
treated with concentrations between 25 and I 00 ~M AJA (Figure 6).

:.0
n:l

>

Figure 6.

ignificant cell death observed in Y-79 cultures with AJA Treatment.

Cells were treated in triplicate with the indicated AJA concentrations. Representative data
are shown. MTS cell viability assay was run at 72 hr post-treatment. Values represent the
average cell viability for triplicate cultures.
indicate statisticaJ significance of p<O.OS.

tandard errors are indicated. Asterisks

Carboplalin 's E_ffec:t on

r- 7 9 Rb cell viability

Y -79 cells were plated in a 96-well plate at a density 3.1 x 105 cells/ well. Wells
vvere treated in triplicate 24 hr later with the follov. ing increasing chemotherapy drug
carboplatin (CBP) concentrations: 25 j..tM. 50 j..tM, 75 j..tM, I 00 j..tM. An MT assay was
used to measure the cell viability after 72 hr. Our results indicate that significant cell
death occurs in Y -79 RB cells when treated with 50 j..tM concentration of CBP (Figure 7).

-
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Figure 7. Y -79 cultures '""ith CBP Treatment.

Cells were treated in triplicate with the indicated CBP concentrations. Representative
data are shown. MT cell viability assay was run at 72 hr post-treatment. Values
represent the average cell viabi lit) for triplicate cultures.

tandard errors are indicated.

Asterisks indicate stati stical significance ofp<0.05.
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E.ffect ofAJA on non-transformed neural-derived cells
Primary mouse astrocytes and microglia were plated and after 24 hr. treated in
triplicate with increasing ajulemic acid concentrations of 50 )..lM, 100 )..lM, and 200 )..lM.
Cell viability was measured at 24 hr using an MTT (3-(4,5-dimethylthiazone-2yl)-2.5diphenylletrazolium bromide) assay. The MTT reagent reacts with a mitochondrial
enzyme that is active when the cell is alive and the chemical reaction yields an insoluble
purple precipitate. Once the cell is lysed, the precipitate is released and the assay
concentration can be measured on a plate reader at 570 nm. The results indicate that AJA
concentrations between 100 and 200 11M become toxic to astrocytes (Figure 8 - Chavis
and Tull, 2007).

110
100
90
~ 80
:..: 70
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.~ 50
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u 20
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Figure 8. Ajulemic acid becomes toxic to non-transformed neural-derived cells at
concentrations between 100 and 200 fJ M. Cells were plated in triplicate and treated
with the indicated concentrations of AJA. MTT cell viability assays were run at 24 hr
post-treatment. Standard errors are indicated. Asterisks indicate statistical signHicance
of p < 0.05 (Chavis and Tull, 2007).
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Possible 1\'europrotection ·with Ajulemic Acid
Primary mouse conical neurons were plated in a 96-wc ll plate. Neurons were
treated with 500 units/ML interferon gamma (INF-y).

ignificant cell death was

observed. Mice neurons were pretreated v.ith 40 J.lM AJA and then treated v.ith 500
units/mL l F-y. Although not significant, less cell death was observed in the cel ls
pretreated with AJA versus the control. Mice neurons were treated with 40 J.lM of AJA
and no significant cell death occurred (Figure 9- Hurst, 2008).
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Figure 9. Neuroprotection with Ajulemic Acid.
ignificant cell death occurred when interferon gamma ( lFN-y) was used to treat mouse
cortical neurons. When treatment included both IFN-y and AlA together. a lower amount
of cell death was observed. There was also a lower amount of cell death observed when
the AJA only treatment was used. MT cel l viabi lity assa} was run at
72 hr post-treatment. Values represent the average for triplicate cultures. tandard errors
are indicated. Asterisks indicate statistical significance of p < 0.05 (llurst, 2008).
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Potential Apoptosis Mechanism ofAjulemic Acid
Expression of caspase-3. an enzyme activated during the apoptotic cascade. was
measured by ELI A. The results indicate that caspase-3 has been expressed in SK-E
Ewing's sarcoma cells when treated with 40 !lM ajulemic acid (Figure 10- Daly, 2008)

..J

-

E
en

:1.

Untreated 1

AJA Pretreat

Figure 10. Caspase-3 ELI A.

K-E

Ewing's sarcoma cells were pretreated v.. ith 40 jlM ajulemic acid and \vere

measured for caspase-3 expression using ELI A assay. Indicated amounts of caspase-3
in jlg/mL were expressed in the untreated and AJA pretreated cells.

tandard errors are

indicated.
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Discussion

The medicinal use of Cannabis· active ingredient THC (tetrahydrocannabinol)
has attracted much attention. However. its psychotropic effects. although not usually
considered addictive. keep it from being socially accepted. Therefore. there has been a
large amount of recent research on its synthetic analog ajulemic acid (AJA) "'hich docs
not cause psychoactive effects. This research has shown AJA 's connection to pain
reduction. anti-inflammatory properties, and tumor reduction without psychoactive
effects. Up until no\.\, there had been no prior research done on the effects of AJA on
retinoblastoma. a neural derived cancerous tumor of the retina.
Cells from human retinoblastoma cell line Y-79 were treated \\ith various
concentrations from 25 to 100 ~M of AJA. Complete cell death was observed after 72 hr
using an MTS assay to measure viabilit). There is significant evidence that ajulemic acid
is a potent retinoblastoma tumor ce ll suppressor.
Ajulemic acid was also used to treat primary mouse astrocy1es and microglia.
Only AJA concentrations above I 00

~M

induced significant cell death. Therefore. AJA

has been shown to significantly kill the Rb tumor cells at concentrations below 100 ~LM
""ithout inducing cell death to the surrounding neuroglial tissue.
Preliminal) data suggest ajulemic acid may also be neuroprotectivc.

ignificant

cell death of primary mouse neurons occurred when treated with the C) tokine interferon
gamma (INF-y) which causes cell apoptosis. However. V¥hen neurons were pretreated
\\ith 40 ~M AJA and were then introduced to the interferon gamma. less cell death
occurred. Although the data was not statistically significant, a greater number of trials
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with larger sample sizes may result in a more concrete answer to AJA's ability to protect
neurons from immune responses such as INF-y.
Ajulemic aci.d's effects on RB cells may be induced through apoptotic
mechanisms. The expression of caspase-3 indicates that apoptosis did occur in cells
treated with AJA. Apoptosis is a preferable method of cell death over necrosis because
cell rupture. as it occurs in necrosis, can cause leakage of lysosomal enzymes that may be
deadly to nearby cells.
In our cell model, at equal concentrations ajulemic acid is more toxic to the Rb
tumor cells than carboplatin, a current chemotherapy drug used for retinoblastoma
treatment. Future research should investigate the effects of Rb tumor viability vvith lower
ajulemic acid concentrations. Lower concentrations of AJA with the same loss of twnor
cell viability could be a more beneficial treatment.
There is great potential for the movement of AJA in the direction of Rb treatment.
Plans include continuing the research on AJA and its effectiveness as a tumor therapeutic
in the hopes that one day, AJA may be a solution for retinoblastoma patients.
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